Linked Life Data

12672175

Source:http://linkedlifedata.com/resource/pubmed/id/12672175

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2003-4-2
pubmed:abstractText
Frontal lobe dementia, or more generally frontotemporal dementia (FTD), includes several clinical entities and, although highly prevalent, lacks any codified therapeutic strategy. The present review is an attempt to depict the main neurochemical correlates of FTD and, as a consequence, to propose the most sound targets for symptomatic drugs. Large scale double-blind controlled clinical trials should be carried out to test any hypothesis: serotonergic agents, glutamate neurotransmission enhancers, monoamine oxidase inhibitors. The recent discovery of tau gene mutations in FTD with Parkinsonism linked to chromosome 17 has reinforced the direct role attributed to abnormal tau proteins (hyperphosphorylation) and thus raised the possibility to target specifically these processes by drugs (aetiopathogenic compounds).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0885-6222
pubmed:author
pubmed:copyrightInfo
Copyright 2003 John Wiley & Sons, Ltd.
pubmed:issnType
Print
pubmed:volume
18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
221-5
pubmed:dateRevised
2008-3-6
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Drug therapy of frontotemporal dementia.
pubmed:affiliation
Laboratory of Clinical and Experimental Pharmacology Faculty of Medicine, University of Rennes I, 2, avenue du Pr. Léon Bernard, CS 34317, F-35043 Rennes cedex, France. Herve.Allain@univ-rennes1.fr
pubmed:publicationType
Journal Article, Review